Glioblastoma  >>  berubicin (RTA 744)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
berubicin (RTA 744) / CNS Pharma, WPD Pharma
2019-004015-31: A phase 2 open-label study of Berubicin in adult patients with Recurrent Gliobastoma Multiforme after failure of standard first line therapy

Not yet recruiting
2
61
Europe
Berubicin, WP 744, Lyophilisate for solution for infusion
WPD Pharmaceuticals Sp. z o.o., WPD Pharmaceuticals Sp. z o.o.
Glioblastoma Multiforme, Glioblastoma Multiforme, Diseases [C] - Cancer [C04]
 
 
2021-003659-40: A study of Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme Un estudio de Berubicina en Pacientes Adultos con Gliobastoma Recidivante Multiforme

Not yet recruiting
2
210
Europe
Berubicin, WP 744, Lyophilisate for solution for infusion, Capsule, hard, Cecenu®
CNS Pharmaceuticals, Inc., CNS Pharmaceuticals, Inc.
Glioblastoma Multiforme (WHO Grade IV) Glioblastoma Multiforme (grado IV de la OMS), Glioblastoma multiforme (GBM) glioblastoma multiforme (GBM), Diseases [C] - Cancer [C04]
 
 
NCT04762069: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
NCT04915404: Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)

Terminated
1/2
5
Europe
Berubicin Hydrochloride
WPD Pharmaceuticals Sp. z o.o., Worldwide Clinical Trials, National Center for Research and Development, Poland
Recurrent Glioblastoma Multiforme
12/23
12/23

Download Options